Awada S, Sayah R, Mansour M, Nabhane C, Hatem G (2023) Assessment of community pharmacists’ knowledge of the differences between generic drugs and biosimilars: A pilot cross-sectional study. J Med Access 7:27550834231167050

Article  PubMed  PubMed Central  Google Scholar 

Chahine B, Ghandour I, Faddoul L (2023) Knowledge and attitude of community pharmacists toward biosimilar medicines: a cross-sectional study in Lebanon. Clin Epidemiol Global Health 21:101287

Article  CAS  Google Scholar 

Iqbal MS (2020) Pharmacists' awareness and perceptions of biosimilars in Saudi Arabia. Asian J Pharmaceutics (AJP) 14(03). https://doi.org/10.22377/ajp.v14i03.3757

El-Dahiyat FA, Kayyali R (2013) Community pharmacists’ perceptions towards generic medicines and their opinions on future generic substitution policy implementation: a descriptive study from Jordan. J Generic Med 10(2):97–104

Article  Google Scholar 

Alkhuzaee FS, Almalki HM, Attar AY, Althubiani SI, Almuallim WA, Cheema E et al (2016) Evaluating community pharmacists’ perspectives and practices concerning generic medicines substitution in Saudi Arabia: a cross-sectional study. Health Policy 120(12):1412–1419

Article  PubMed  Google Scholar 

El-Jardali F, Fadlallah R, Morsi RZ, Hemadi N, Al-Gibbawi M, Haj M et al (2017) Pharmacists’ views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study. Implement Sci 12:1–13

Article  Google Scholar 

Wouters OJ, Kanavos PG, Mc KM (2017) Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. Milbank Q 95(3):554–601

Article  PubMed  PubMed Central  Google Scholar 

Troein P, Newton M, Scott K, Mulligan C (2019) The impact of biosimilar competition in Europe. Parsippany (NJ): IQVIA institute for Human Data and Science. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2022.pdf

Ahlstrom A, King R, Brown R, Glaudemans J, Mendelson D (2007) Modeling federal cost savings from follow-on biologics. Avalere Health LLC., Washington DC

Google Scholar 

Mulcahy AW, Hlávka JP, Case SR (2018) Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q 7(4):3

PubMed  PubMed Central  Google Scholar 

FDA USFaDA (n.d.) Scientific considerations in demonstrating biosimilarity to a reference product. 2021 [Available from: https://www.fda.gov.

Fasseeh AN, Elezbawy B, El-Fass KA, GamaI M, Seyam A, Hayek N et al (2023) Maximizing the benefits of using biosimilars in Egypt. J Pharmaceutical Policy Practice 16(1):79

Article  Google Scholar 

Abduelkarem AR, Othman AM, Elgendy SM, Moustafa RE, Al-Areqi NM (2019) Physician and patient’s insights towards generic prescribing: the scenario in the United Arab Emirates. J Generic Med 15(4):193–202

Article  Google Scholar 

Mahmoud Soliman WO, Shehata AI, Mosallam RA (2022) International Nonproprietary Names prescription in a specialized public hospital in Egypt. J Generic Med 18(4):223–232

Article  Google Scholar 

Kamphuis BW, Kanavos P (2021) Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy Open 2:100045

Article  PubMed  PubMed Central  Google Scholar 

Jordan Food and Drug Administration (JFDA) (2017) Instructions of changes to drugs registered in 2017. JFDA, https://www.jfda.jo/EchoBusV3.0/SystemAssets/Documents/AR/DRUGD.

El-Dahiyat F, Kayyali R (2013) Community pharmacists’ perceptions towards generic medicines and their opinions on future generic substitution policy implementation: a descriptive study from Jordan. J Generic Med: Business J Generic Med Sector 10:97–104

Article  Google Scholar 

Hatem G, Navasardyan N, Lahoud E, Awada S, Itani R, Ajrouche R et al (2022) Predictors of substitution to generic drugs and physicians’ perceived exclusivity of substitution: a cross sectional survey among physicians. J Generic Med: Business J Generic Med Sector 19:174113432211075

Google Scholar 

Chahine B et al (2023) Knowledge and attitude of community pharmacists toward biosimilar medicines: a cross-sectional study in Lebanon. Clin Epidemiol Glob Health 21:101287

Edgar BS, Cheifetz AS, Helfgott SM, Smith GP, Bandekar T, Hoye-Simek A et al (2021) Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm 27(8):1129–1135

PubMed  Google Scholar 

Saleh S, Abou Samra C, Jleilaty S, Constantin J, El Arnaout N, Dimassi H et al (2017) Perceptions and behaviors of patients and pharmacists towards generic drug substitution in Lebanon. Int J Clin Pharm 39(5):1101–1109

Article  PubMed  Google Scholar 

WHO (2022) World Health Organization, Glossary [Available from: https://extranet.who.int/pqweb/content/glossary.

EMA EMA (2023) Biosimilar medicines: Overview. [Available from: https://www.ema.europa.eu.

WHO (2022) World Health Organization Guidelines on evaluation of biosimilars. [Available from: https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars.

Toklu HZ, Dülger GA, Hıdıroğlu S, Akici A, Yetim A, Gannemoğlu HM et al (2012) Knowledge and attitudes of the pharmacists, prescribers and patients towards generic drug use in Istanbul - Turkey. Pharm Pract (Granada) 10(4):199–206

Article  PubMed  Google Scholar 

Alsufyani MH, Alghoribi MH, Bin Salman TO, Alrabie AF, Alotaibi IS, Kharbosh AM et al (2023) Generic substitutions and therapeutic interchanges in hospital pharmacies: a qualitative study from western Saudi Arabia. Healthcare (Basel) 11(13):1893

Article  PubMed  Google Scholar 

World Population Review: MENA Countries 2024 2024 [cited 2025 Feb 18 2025]. Available from: https://worldpopulationreview.com/country-rankings/mena-countries.

O’Sullivan A, Rey M-E, Mendez JG (2011) Opportunities and Challenges in the MENA Region. Arab World Competitiveness Rep 2012:42–67

Google Scholar 

Hajjar R, Atli T, Al-Mandhari Z, Oudrhiri M, Balducci L, Silbermann M (2013) Prevalence of aging population in the Middle East and its implications on cancer incidence and care. Annals Oncol 24:vii11–vii24

Article  Google Scholar 

Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M et al (2023) Cochrane handbook for systematic reviews of interventions, version 6.4. Cochrane. London. Available from https://www.training.cochrane.org/handbook

Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, Roen K, Duffy S (2006) Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Programme. https://doi.org/10.13140/2.1.1018.4643

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj 372:n71

Toverud E-L, Hartmann K, Håkonsen H (2015) A systematic review of physicians’ and pharmacists’ perspectives on generic drug use: what are the global challenges? Appl Health Econ Health Policy 13:35–45

Article  PubMed Central  Google Scholar 

Sarnola K, Merikoski M, Jyrkkä J, Hämeen-Anttila K (2020) Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open 10(5):e034183

Article  PubMed  PubMed Central  Google Scholar 

Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S (2023) Chapter 2: determining the scope of the review and the questions it will address. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from: https://www.training.cochrane.org/handbook

World-Bank (2013) Fairness and accountability: engaging in health systems in the Middle East and North Africa. World Bank Washington. Available from: https://documents.worldbank.org/en/publication/documents-reports/documentdetail/223181468299192501/fairness-and-accountability-engaging-in-health-systems-in-the-middle-east-and-north-africa

Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P et al (2018) The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Educ Inf 34(4):285–291

Google Scholar 

Abdulah DM, Perot KA (2019) Factors influencing prescribing perceived utility of drugs: experiences from Iraqi Kurdistan. Innovations Pharm 10(4):19

Article  Google Scholar 

Abusara OH, Bishtawi S, Al-Qerem W, Jarrar W, Al-Khareisha L, Khdair SI (2023) Pharmacists’ knowledge, familiarity, and attitudes towards biosimilar drugs among practicing Jordanian pharmacists: A cross sectional study. J King Saud Univ Sci 35(6):102767

Article  Google Scholar 

Alahmari A, Almalki Z, Iqbal M, Alossaimi M, Alsaber M, Alanazi R et al (2021) Knowledge and Attitude of Pharmacists about Biosimilar Medications in Saudi Arabia. Int J Pharm Investigation 11:123–126

Article  Google Scholar 

Albadr Y, Khan TM (2015) Factors influencing community pharmacist decision to dispense generic or branded medicines; Eastern Province, Alahsa. Saudi Arabia Saudi Pharm J 23(2):143–146

Article  PubMed  Google Scholar 

Alkhuzaee FS, Almalki HM, Attar AY, Althubiani SI, Almuallim WA, Cheema E et al (2016) Evaluating community pharmacists’ perspectives and practices concerning generic medicines substitution in Saudi Arabia: A cross-sectional study. Health Policy 120(12):1412–1419

Article  PubMed  Google Scholar 

Almadany R, Omair MA, Al Rayes H, Almalag HM, Alshamsan A (2022) Perception of biosimilar biologics and non-medical prescription switching among rheumatologists: a Saudi Society for Rheumatology initiative. Saudi Pharm J 30(1):39–44

Article  PubMed  Google Scholar 

Almalki ZS, Iqbal MS, Alossaimi MA, Lasaf AM, Almawash BA, Aldossary FH et al (2020) Physicians’ knowledge and awareness about biosimilars in Saudi Arabia: What is imperative to know ? J Young Pharm 12(3):280–284

Article  Google Scholar 

Almalki ZS, Iqbal MS, Alossaimi MA, Alsaber MZ, Alanazi RA, Alruwaili YM et al (2020) Pharmacists’ awareness and perceptions of biosimilars in Saudi Arabia. Asian J Pharm 14(3):417–421

Google Scholar 

Al-Saadi A, Haridass S, Nouri A (2023) Knowledge, attitude, perception, and practices of generic substitution of community pharmacists in the north al-Batinah governorate of Oman: a pilot study. Palest Med Pharm J 8(2):1–16

Article  Google Scholar 

Alsufyani MH, Alghoribi MH, Bin Salman TO, Alrabie AF, Alotaibi IS, Kharbosh AM et al (2023) Generic substitutions and therapeutic interchanges in hospital pharmacies: a qualitative study from western Saudi Arabia. Healthcare 11(13):1893

Article  PubMed  PubMed Central  Google Scholar 

Awada S, Sayah R, Mansour M, Nabhane C, Hatem G (2023) Assessment of community pharmacists’ knowledge of the differences between generic drugs and biosimilars: A pilot cross-sectional study. J Med Access 7:27550834231167050–275508342311670